Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 16/20 | 0.54 |
| ▸ | P2RY4 | P51582 | 10/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7168349 | 1.00 | P2RY2 (0.54) | P2RY2P2RY4P2RY6 | |
| Lysine SCHEMBL28656282 | 0.86 | P2RY2 (0.61) | P2RY2P2RY4P2RY6 | |
| SCHEMBL6141694 | 0.84 | LMNA (0.58) | — | |
| SCHEMBL6142111 | 0.84 | LMNA (0.58) | — | |
| Cystetine Triphosphate SCHEMBL315351 | 0.80 | P2RY2 (0.80) | P2RY2P2RY4P2RY6 | |
| Cystetine Triphosphate SCHEMBL21311175 | 0.80 | P2RY2 (0.80) | P2RY2P2RY4P2RY6 | |
| Cystetine Triphosphate SCHEMBL104629 | 0.80 | P2RY2 (0.80) | P2RY2P2RY4P2RY6 | |
| Cystetine Triphosphate SCHEMBL105273 | 0.80 | P2RY2 (0.80) | P2RY2P2RY4P2RY6 | |
| Cystetine Triphosphate SCHEMBL15810768 | 0.80 | P2RY2 (0.80) | P2RY2P2RY4P2RY6 | |
| Cystetine Triphosphate SCHEMBL10044131 | 0.80 | P2RY2 (0.80) | P2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6617438-B1 | Nucleic acid of given formula; ribozyme able to cleave RNA of HER2 gene; use as anticarcinogenic agent | SIRNA THERAPEUTICS, INC. | 2003-09-09 | — | — | US | disclosed |
| US-6528640-B1 | Of given formula; can use to inhibit HER2/neu/ ErbB2 gene expression; anticarcinogenic agents | RIBOZYME PHARMACEUTICALS, INCORPORATED | 2003-03-04 | — | — | US | disclosed |
| US-20030004122-A1 | Nucleotide triphosphates and their incorporation into oligonucleotides | RIBOZYME PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| US-6482932-B1 | Nucleoside triphosphates and their incorporation into oligonucleotides | RIBOZYME PHARMACEUTICALS, INCORPORATED | 2002-11-19 | — | — | US | disclosed |
| EP-1212416-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016312-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004122-A1 | Nucleotide triphosphates and their incorporation into oligonucleotides | NTPCR, DNTT, RNGTT | P2RY2 234/4885P2RY4 260/4885P2RY6 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.